Basic Prometrium Information

• INN (International Nonproprietary Name): Progesterone.
• Brand Names Available In Canada (English): Prometrium capsules 100 mg and 200 mg in blister packs (30/90-count), marketed under Prometrium packaging similar to US/Canada presentations.
• ATC Code: G03DA04 (Genito-Urinary System And Sex Hormones; Progestogens; Pregnen-(4)-Derivatives).
• Forms & Dosages: Soft capsules 100 mg and 200 mg in blister packs (30/90); vaginal capsules/softgels 100 mg and 200 mg (boxes of 15/30); compounding powders available rarely from specialty compounding pharmacies.
• Manufacturers In Canada (English): AbbVie listed as global manufacturer of Prometrium; multiple generics and international suppliers (Teva, Mylan and others) supply micronized progesterone products.
• Registration Status In Canada (English): Not specified.
• OTC / Rx Classification: Prescription only (Rx).

Major 2022–2025 Canadian & Global Studies

Patients and clinicians ask whether micronized progesterone is still the go-to choice for luteal support and HRT protection.

High-quality systematic reviews and randomized trials from 2022–2025 consistently show three trends: micronized progesterone formulations, including oral softgels such as Prometrium, remain widely used for luteal-phase support in assisted reproductive technology and for endometrial protection in combined HRT.

Comparisons of oral versus vaginal routes report similar clinical pregnancy and live-birth outcomes in fertility settings, while tolerability and local effects differ between routes.

Safety surveillance in this period reinforced known contraindications such as severe liver disease and hormone-dependent cancers, and highlighted formulation-specific considerations like oil excipients and allergen labelling.

Canadian cohort analyses and international meta-analyses emphasise patient-centred outcomes such as mood and sedation, and pharmacokinetic data for micronized progesterone that guide clinic prescribing choices.

Main Outcomes

Micronized progesterone performs comparably to alternatives for pregnancy outcomes when used appropriately for luteal support.

Safety Observations

Post-market signals focus on sedation, mood effects and excipient-related allergic reactions, prompting clearer labelling in some regions.

Layman’s Explanation

Patients often want to know why progesterone is used in HRT and fertility care.

Progesterone is the body’s natural progestogen that prepares and maintains the uterine lining for implantation and balances oestrogen during hormone therapy.

Micronized oral formulations improve gastrointestinal absorption so the hormone reaches target tissues more reliably than crude preparations.

Many people feel micronized progesterone has fewer synthetic-progestin-like side effects, and some prefer it for its “natural” profile when discussing options with clinicians.

Scientific Breakdown

At the cellular level, progesterone binds intracellular progesterone receptors (PR-A and PR-B) and changes gene transcription to induce secretory transformation of endometrial stroma.

This action stabilizes the uterine lining and reduces risk of endometrial hyperplasia when progesterone is combined with oestrogen in HRT regimens.

Micronization increases particle surface area and improves oral bioavailability compared with non-micronized forms.

Peak plasma levels and first-pass hepatic metabolism vary by route of administration; oral dosing yields more systemic exposure while vaginal dosing favours local tissue levels.

Typical registrational dosing (per product monographs) informs clinical regimens such as 200 mg nightly for endometrial protection and variable 100–400 mg regimens for luteal support in fertility care.

Health Canada Approvals (DIN-Based)

Clinicians and pharmacists verify approved uses and DINs before prescribing or dispensing.

Prometrium (micronized progesterone softgels) appears in international product listings for 100 mg and 200 mg strengths consistent with Prometrium packaging used in the US and Canada markets.

Indications align with standard regulatory labels such as secondary amenorrhea and endometrial protection in women receiving oestrogen therapy.

Prescribers should check the active product’s DIN and current Health Canada monograph at the time of prescribing and on provincial drug benefit lists.

Notable Off-Label Trends In Canadian Practice

Canadian fertility clinics commonly use micronized progesterone for luteal support in IVF and related assisted reproductive technology cycles.

Off‑label vaginal administration of oral capsules is practiced in some centres to provide local endometrial support, though this route is not always explicitly Health Canada‑labelled.

Compounded and alternative preparations are used for special patient needs but require clinic oversight and awareness of regulatory limits.

General Dosing Per Health Canada Monographs

Standard regimens from product monographs remain the reference for prescribing.

For secondary amenorrhea the usual regimen is 400 mg orally once nightly for 10 days, repeated as prescribed.

For endometrial protection with oestrogen the standard regimen is 200 mg orally once nightly for 12 days of a 28‑day cycle.

Always confirm the local monograph and DIN sheet for the specific marketed product before advising patients.

Condition-Specific Dosing Adjustments

Luteal-support regimens used in assisted reproductive technology vary by clinic protocol and patient factors.

Common practice is 100–200 mg oral nightly, while some protocols use vaginal dosing adjusted to embryo transfer timing.

Elderly patients require clinical monitoring for sensitivity but routine dose reduction is not mandated by monographs.

Severe hepatic impairment is an absolute contraindication; avoid use or consult a specialist for mild to moderate hepatic dysfunction.

If a dose is missed, take it when remembered unless it is close to the next dose; overdose care is supportive for nausea, sedation and withdrawal bleeding.

Contraindications (Canadian Advisories)

Prometrium should not be used in people with severe liver dysfunction, known or suspected breast or other hormone‑dependent malignancy, or undiagnosed abnormal vaginal bleeding.

Active or previous thromboembolic events (DVT, PE, stroke, myocardial infarction) are absolute contraindications per product information.

Allergy to capsule excipients is important; some formulations contain peanut oil and carry allergen warnings.

Pharmacists and prescribers must check DIN-specific warnings and provincial formulary advisories before dispensing.

Adverse Effects (Post-Market Reports)

Common adverse effects reported include headache, breast tenderness, abdominal cramps, dizziness, fatigue and mood changes.

Post-market surveillance from 2022–2025 highlighted sedation and excipient-related allergic reactions as notable issues.

Psychiatric events such as worsening depression and rare hepatic enzyme elevations have been reported and warrant monitoring.

Adverse events should be reported through Health Canada’s Canada Vigilance Program by clinicians, pharmacists or patients.

Food Interactions Common In Canadian Diet

Micronized progesterone absorption can be affected by food because fat-containing meals may alter peak plasma concentrations.

To reduce variability, advise patients to take Prometrium consistently at bedtime with or without a light snack according to the product monograph.

Given common higher-fat meals in typical Western diets, consistent timing around sleep helps reduce swings in systemic exposure and sedation risk.

Drug Combinations Flagged By Health Canada

Concomitant use of enzyme inducers such as rifampin, certain anticonvulsants and St John’s wort may lower progesterone levels and compromise efficacy.

Strong CYP3A4 modulators can affect progesterone metabolism and should be reviewed before co-prescribing.

Combining progesterone with oestrogens requires planned regimens to ensure endometrial protection; pharmacists at community chains routinely screen interactions at dispensing.

Canadian Survey Data

Many patients in Canada report high perceived efficacy with micronized progesterone for HRT and in fertility contexts.

Survey and clinic feedback from 2022–2025 show tolerability differences are a major factor in choosing oral versus vaginal routes.

Sedation and mood changes are commonly cited concerns that influence shared decision-making between clinician and patient.

Patients frequently express a preference for “natural” progesterone over synthetic progestins when informed of options and trade-offs.

Forum And Community Pharmacy Trends

Common practical questions at pharmacy counters include capsule size and swallowing, peanut-oil allergy concerns, cost and provincial coverage frustrations.

Community pharmacists report frequent counselling on bedtime dosing to reduce daytime drowsiness and on how to inspect capsules for integrity.

In fertility care, clinics and pharmacists discuss route choice based on tolerability, pharmacokinetics and formulary coverage rather than strict approval language.

National Pharmacy Chains

Prometrium and micronized progesterone generics are stocked at major Canadian chains such as Shoppers, Rexall, Jean Coutu and London Drugs, with availability varying by province and pack size.

Pharmacists verify DIN and manufacturer (for example, AbbVie) at dispensing to confirm product identity and coverage.

Online Pharmacy Availability & Provincial Restrictions

Authorized online pharmacies operating in Canada may dispense Prometrium with a valid prescription, subject to provincial rules.

Public drug plans such as the Ontario Drug Benefit, BC PharmaCare and RAMQ list progesterone products variably and often require indication-specific prior authorization for coverage.

Patients should confirm prior-authorization criteria before ordering to avoid unexpected out-of-pocket expenses.

Cross-Border US Comparisons

US packaging and pricing can look different, with Prometrium blister design in orange/yellow and clear peanut allergen labelling on some US packs.

While US prices may appear lower out-of-pocket, importation rules and valid prescription requirements limit cross-border procurement for Canadian patients.

Pharmacists should review provincial reimbursement rules, dispensing fees and excipient labelling differences when advising on sourcing.

Comparison Of DIN-Approved Alternatives

Alternatives available in Canada include synthetic progestins such as medroxyprogesterone acetate (Provera/generics) and dydrogesterone (Duphaston where available), along with micronized progesterone generics.

Synthetic progestins differ in receptor activity and metabolic effects compared with natural progesterone, and dydrogesterone is noted for lacking androgenic effects.

Pros And Cons Checklist

Pros of micronized progesterone include natural hormone structure, established endometrial protection when used with oestrogen, and patient preference for “natural” options.

Cons include potential sedation, excipient-related allergy risk (peanut oil in some formulations) and variable cost/coverage across provinces.

Synthetic progestins are often less sedating and less expensive, but they are pharmacologically distinct and may have different metabolic or cardiovascular signals in some study contexts.

Health Canada Approval Process

Progesterone products are regulated with assignment of a Drug Identification Number (DIN) and evaluated for safety, quality and efficacy prior to marketing authorisation.

Manufacturers submit evidence for indication-specific claims and must comply with Health Canada labelling, pharmacovigilance and post-market reporting obligations.

DIN And Bilingual Labelling Rules

All marketed products in Canada require a DIN and bilingual English/French labelling for national distribution.

Packaging must list allergens where applicable; US peanut allergen warnings for certain Prometrium packs highlight excipient concerns that Canadian packaging addresses per regulatory guidance.

Pharmacists should verify DIN to confirm product equivalence and coverage for public drug plans.

Consolidated FAQ

Q: Is Prometrium available in Canada and covered by provincial drug plans?

A: Yes—micronized progesterone products such as Prometrium in 100 mg and 200 mg strengths are marketed in Canada, but coverage varies by province and indication, so check ODB, BC PharmaCare or RAMQ for criteria and prior-authorization rules.

Q: Can I use oral Prometrium vaginally for fertility?

A: Off‑label vaginal administration of oral capsules is practised in some fertility clinics for local endometrial support; discuss this with your fertility clinic and pharmacist because it is not universally Health Canada‑labelled.

Q: What if I have a peanut allergy?

A: Some capsule formulations contain peanut oil; inspect packaging and the product monograph or ask a pharmacist to select a formulation without this excipient or an alternative progestogen.

Q: How do I report side effects in Canada?

A: Report adverse events via Health Canada’s Canada Vigilance Program; clinicians and pharmacists can assist with reporting.

Visual Guide

Design an infographic set with four panels: a dosage flowchart mapping indication to recommended dose, a provincial coverage map colour-coded for typical prior-authorization triggers, purchase channels showing community chains and authorised online pharmacies, and a safety panel listing contraindications and the peanut-oil allergen icon.

Include DIN fields and bilingual callouts in English and French, and cite the product monograph and Health Canada sources in a footer for credibility.

Canadian Household Storage Guidelines

Store Prometrium softgels below 25°C (77°F) in their original blister packaging and protect them from moisture and light.

Do not refrigerate or freeze the capsules, and keep them out of reach of children.

Original packaging helps protect capsules from humidity common in coastal regions and humid summers.

Cold-Chain Storage Where Applicable

Prometrium does not require cold-chain storage, but extreme winter shipments across provinces should be insulated to prevent freezing during transit.

Patients ordering online should receive packages promptly and inspect capsules for cracking or discolouration, and pharmacists should document any temperature excursions per provincial pharmacy regulations.

Advice From Canadian Pharmacists

Pharmacist counselling should confirm the indication, verify the DIN, and review bedtime dosing to mitigate sedation.

Counselling should include excipient checks for peanut oil, screening for contraindications such as liver disease or thromboembolism, and verification of formulary coverage.

Provide written counselling in English and French and document interaction checks in the patient record.

Provincial Health Authority Guidance

Follow provincial prescribing guidelines for HRT and fertility services and check for prior-authorisation requirements when seeking public coverage.

Use shared decision‑making to discuss oral versus vaginal routes, side-effect profiles, cost implications and monitoring plans for psychiatric or hepatic concerns.

Report adverse events through Canada Vigilance and liaise with specialists for complex cases.

Purchase And Access Note

In our online pharmacy, prometrium is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Delivery Across Canada (English)

Final Notes For Clinicians And Pharmacists

Always verify the product monograph and DIN before making clinical decisions or dispensing.

Be vigilant about contraindications such as severe hepatic disease and hormone-dependent malignancy, and screen for excipient allergies including peanut oil.

Use shared decision-making when discussing oral versus vaginal routes, and document counselling in both English and French when required by provincial regulations.